Story perspectives

Johnson & Johnson Acquires Halda for $3.05 Billion

11/17/2025

Summary

Story summary

Johnson & Johnson (J&J) has announced the acquisition of Halda Therapeutics for $3.05 billion in cash.
The move aims to bolster J&J's oncology portfolio, particularly for prostate cancer.
Halda's RIPTAC platform offers a novel approach to targeted therapies and may help overcome tumor drug resistance.
The deal is expected to close in early 2026 and will reduce J&J's earnings per share by 15 cents due to financing costs and employee payouts.
The acquisition follows J&J's earlier $14.6 billion purchase of Intra-Cellular Therapies, signaling a significant expansion of its cancer treatment capabilities.

History

Historical Context

Johnson & Johnson's acquisition of Centocor in 1999 for $4.9 billion marked a pivotal expansion into biotechnology, enhancing its capabilities in immunology and oncology. This trend continued with the 2023 purchase of Halda Therapeutics for $3.05 billion, reflecting the pharmaceutical industry's shift towards targeted cancer therapies. Such strategic acquisitions are essential for J&J to maintain its competitive edge in a rapidly evolving market.

1 of 2

Story summary

Johnson & Johnson (J&J) has announced the acquisition of Halda Therapeutics for $3.05 billion in cash.
The move aims to bolster J&J's oncology portfolio, particularly for prostate cancer.
Halda's RIPTAC platform offers a novel approach to targeted therapies and may help overcome tumor drug resistance.
The deal is expected to close in early 2026 and will reduce J&J's earnings per share by 15 cents due to financing costs and employee payouts.
The acquisition follows J&J's earlier $14.6 billion purchase of Intra-Cellular Therapies, signaling a significant expansion of its cancer treatment capabilities.

1 / 2